Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28.5M
-
Number of holders
-
53
-
Total 13F shares, excl. options
-
60.7M
-
Shares change
-
-5.01M
-
Total reported value, excl. options
-
$19.5M
-
Value change
-
-$2.59M
-
Number of buys
-
21
-
Number of sells
-
-27
-
Price
-
$0.32
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q4 2022
66 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q4 2022.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 53 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60.7M shares
.
Largest 10 shareholders include BROADWOOD CAPITAL INC (23.4M shares), PURA VIDA INVESTMENTS, LLC (18.1M shares), AWM Investment Company, Inc. (7.25M shares), VANGUARD GROUP INC (4.36M shares), Defender Capital, LLC. (2.27M shares), BlackRock Inc. (1.42M shares), GEODE CAPITAL MANAGEMENT, LLC (992K shares), MILLENNIUM MANAGEMENT LLC (561K shares), Schonfeld Strategic Advisors LLC (424K shares), and STATE STREET CORP (282K shares).
This table shows the top 53 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.